Dimensional Fund Advisors LP Has $87.88 Million Stock Holdings in GSK plc (NYSE:GSK)

Dimensional Fund Advisors LP boosted its position in shares of GSK plc (NYSE:GSK - Free Report) by 0.7% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 2,598,570 shares of the pharmaceutical company's stock after buying an additional 18,492 shares during the quarter. Dimensional Fund Advisors LP owned approximately 0.13% of GSK worth $87,884,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the company. Indiana Trust & Investment Management Co lifted its stake in shares of GSK by 200.0% during the fourth quarter. Indiana Trust & Investment Management Co now owns 750 shares of the pharmaceutical company's stock valued at $25,000 after acquiring an additional 500 shares during the period. Crews Bank & Trust acquired a new stake in shares of GSK during the 4th quarter worth approximately $26,000. ST Germain D J Co. Inc. raised its stake in shares of GSK by 195.5% during the fourth quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company's stock worth $27,000 after buying an additional 522 shares during the last quarter. Sierra Ocean LLC bought a new position in GSK in the fourth quarter valued at approximately $32,000. Finally, Parkside Financial Bank & Trust boosted its stake in GSK by 470.1% in the fourth quarter. Parkside Financial Bank & Trust now owns 992 shares of the pharmaceutical company's stock valued at $34,000 after acquiring an additional 818 shares during the last quarter. 15.74% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

GSK has been the topic of several recent research reports. StockNews.com upgraded GSK from a "buy" rating to a "strong-buy" rating in a research report on Thursday, April 24th. BNP Paribas started coverage on GSK in a research report on Tuesday, April 15th. They set a "neutral" rating and a $35.25 target price for the company. Hsbc Global Res upgraded shares of GSK to a "strong sell" rating in a research report on Monday. Finally, Morgan Stanley began coverage on shares of GSK in a report on Wednesday, February 12th. They set an "equal weight" rating for the company. One analyst has rated the stock with a sell rating, eight have issued a hold rating and four have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, GSK has an average rating of "Moderate Buy" and a consensus target price of $40.58.

GSK Stock Up 0.7 %

Shares of GSK stock traded up $0.29 on Friday, hitting $39.04. The company had a trading volume of 4,287,271 shares, compared to its average volume of 4,741,494. The stock has a 50-day moving average of $37.67 and a 200-day moving average of $36.04. The company has a debt-to-equity ratio of 1.12, a current ratio of 0.78 and a quick ratio of 0.52. GSK plc has a twelve month low of $31.72 and a twelve month high of $45.93. The firm has a market capitalization of $80.55 billion, a P/E ratio of 24.55, a P/E/G ratio of 1.12 and a beta of 0.56.

GSK (NYSE:GSK - Get Free Report) last released its earnings results on Wednesday, April 30th. The pharmaceutical company reported $1.13 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.08 by $0.05. The firm had revenue of $10.06 billion during the quarter, compared to analysts' expectations of $7.52 billion. GSK had a return on equity of 48.59% and a net margin of 8.13%. The company's revenue was up 2.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.43 EPS. Research analysts predict that GSK plc will post 4.14 earnings per share for the current year.

GSK Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, July 10th. Stockholders of record on Friday, May 16th will be paid a dividend of $0.4216 per share. This is a boost from GSK's previous quarterly dividend of $0.39. This represents a $1.69 annualized dividend and a dividend yield of 4.32%. The ex-dividend date of this dividend is Friday, May 16th. GSK's dividend payout ratio (DPR) is currently 100.63%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.